Full-Time

HCM Therapeutic Lead

Posted on 8/26/2024

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function disorders

Compensation Overview

$1 - $350k/hr

Senior, Expert

Remote in USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • MD/DO (cardiovascular and HCM training and clinical research and/or Medical Affairs experience preferred, board certification/eligibility desirable) with 8+ years of related experience
  • Medical Affairs experience with medicine approvals and peri-launch activities
  • Background in academic medicine, clinical research, and familiarity with biostatistics and epidemiology are highly desirable
  • Prior experience in the biotech/pharmaceutical industry is a plus
  • Familiarity with OPDP, PhRMA code, and key regulations in the pharmaceutical industry is a plus
  • Proven ability to work independently and as a member of an integrated, interdisciplinary team in carrying out assigned responsibilities
  • Must be analytical and articulate in both oral and writing skills, possess excellent presentation skills, with a demonstrated ability to communicate well with others at varying professional levels
  • Proficiency with Microsoft Office
  • Ability to travel domestically and internationally (~30% of the time)
Responsibilities
  • Serve as the Global Medical Affairs lead for the launch of aficamten, including development of strategic vision, execution of medical launch activities, and education of HCPs
  • Lead and manage day‐to‐day clinical and medical guidance while working closely on joint projects with other members of the Medical Affairs team and other departments within Cytokinetics and our business partners. Projects may include scientific congress/conference strategy and planning, advisory boards, field force training, review of medical information standard response letters, health economics and epidemiology analyses, and marketing/policy related projects.
  • Partner with European and ex-US Medical Affairs and cross-functional personnel to assure global harmonization of aficamten efforts and data promulgation
  • Expand and maintain an active global KOL HCM expert network
  • Lead scientific input into publication strategy for the HCM therapeutic area, including review of abstracts and posters for presentation at scientific meetings and manuscripts for publication
  • Establish the scientific and clinical priorities for an investigator sponsored study program and chair the internal review committee that adjudicates submitted research proposals
  • Serve as Medical lead on appropriate cross‐functional Medical and Commercial teams to inform brand strategies and tactics for aficamten
  • Lead strategic planning and implementation of HCM medical education, grant, and sponsorship programs
  • Provide clinical and scientific support in responding to inquiries from healthcare professionals
  • Support the Medical Affairs review of medical and promotional scientific materials related to HCM and aficamten
  • Present data at company advisory board meetings and training programs
  • Lead specific data generation projects to address identified medical data gaps
  • Identify and effectively interact with HCM external experts to engage in scientific exchange to meet the needs of patients and the medical community
  • Collaborate with HEOR function to define HCM research strategy and design of studies
  • Lead Medical content for Medical Affairs initiatives including collaboration with the MSL team including the development of materials for external medical interactions and to address healthcare professional inquiries
  • Upon initiation of a Phase 4 program, lead the review and adjudication of investigator-initiated research proposals

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal of Cytokinetics is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.

Company Size

501-1,000

Company Stage

IPO

Headquarters

South San Francisco, California

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased demand for targeted therapies aligns with Cytokinetics' muscle activators and inhibitors.
  • FDA initiatives expedite approval for rare disease drugs, benefiting Cytokinetics' ALS and SMA pipeline.
  • Collaborations with tech firms accelerate drug discovery, enhancing Cytokinetics' R&D efforts.

What critics are saying

  • Competition from similar biopharmaceuticals could impact Cytokinetics' market share and profitability.
  • Potential clinical trial delays due to regulatory scrutiny could hinder drug commercialization.
  • Sanofi's rights acquisition for Aficamten in China may affect Cytokinetics' market strategy.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle activators and inhibitors for cardiovascular and neuromuscular diseases.
  • The company has a robust pipeline including omecamtiv mecarbil and reldesemtiv.
  • Cytokinetics' EARTH-HCM initiative raises awareness for hypertrophic cardiomyopathy.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-1%
Here Novi
Mar 21st, 2025
Cytokinetics Launches EARTH-HCM for Hypertrophic Cardiomyopathy Awareness

Cytokinetics launches EARTH-HCM for hypertrophic cardiomyopathy awareness.

Investing.com
Mar 20th, 2025
Cytokinetics launches interactive HCM public health tool

Cytokinetics launches interactive HCM public health tool.

Medical Update Online
Mar 19th, 2025
Cytokinetics to present new findings on Aficamten and hypertrophic cardiomyopathy at ACC 2025

Cytokinetics to present new findings on Aficamten and hypertrophic cardiomyopathy at ACC 2025.

Stock Titan
Jan 6th, 2025
Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) - Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:00 AM Pacific Time in the Borgia Room of the Westin St. Francis Hotel in San Francisco, CA.

BioSpace
Dec 20th, 2024
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China

Cytokinetics announces Sanofi acquired rights to develop and commercialize Aficamten in Greater China.

INACTIVE